Brickell Biotech Inc

-0.01 (-3.03%)
Mergers / Acquisitions

Brickell Biotech Acquires Exclusive Rights To Phase 1-Ready Dyrk1a Inhibitor Program And Novel Platform Targeting Autoimmune And Inflammatory Diseases

Published: 09/01/2021 11:35 GMT
Brickell Biotech Inc (BBI) - Brickell Biotech Acquires Exclusive Rights to Phase 1-ready Dyrk1a Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases.
Brickell Biotech Inc - Acquisition Includes Rights to Platform of Dyrk1a Inhibitors.
Brickell Biotech Inc - Brickell Will Make a One-time Payment to Voronoi of $2.5 Million in Cash and $2.5 Million in Shares of Brickell Common Stock.
Brickell Biotech Inc - Number of Shares to Be Issued to Voronoi is Based on a Price of $0.89 per Share.